Don - I was just rereading a post of yours on Yahoo from May 29, 2009 and I am interested in your further opinion of the selection of the participants in SUCCEED.
You offered an explanation that said that SUCCEED participants might have been enrolled based on the stability of their disease, e.g. on their percieived ability to permit Rida more time to work, etc. You wrote:
"So the key is to identify those patient populations that will most likely benefit from ridaforolimus which is precisely why the patient enrollment in Phase 3 was different than that in Phase 2.
I recall that Ariad developed (patent pending) a test to determine which mTOR among those available might work better in any particular patient.
Apart from possibly enrolling patients that were more stable, how else do you think that enrolled patients were pre-screened... based on the mTOR selection testing, and/or some other criteria to select candidates that would most benefit?
Also, is there any data on how long the PFS interval is for Sarcoma patients under existing protocols, i.e. without mTOR treatment (or placebo)?
I'm thinking the the final data will be available Dec. Do you agree?
Again, thank you in advance for your insights.
